a:5:{s:8:"template";s:3333:" {{ keyword }}

{{ links }} ";s:4:"text";s:4962:"
Alnylam was founded to help people who lack adequate treatment options live fuller, healthier lives.

Follow Us: Clinical Trials Sign up for updates News Capella … In 2018, our first medicine, ONPATTRO® (patisiran), became the world’s first approved RNAi therapeutic. The following content may not be associated with Alnylam Pharmaceuticals. Their needs drive our discoveries, and their stories further our commitment to delivering innovative therapies.Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, hypercholesterolemia, and primary hyperoxaluria type 1.Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines.

Our RNAi therapies leverage two distinct approaches to enable delivery of small interfering Ribonucleic Acid (siRNA): lipid nanoparticles (LNP) and GalNAc-conjugates.We are developing a new class of innovative medicines calledWe are growing quickly and hiring across North America, Europe, Asia, and Latin America for a wide variety of roles.

Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi into innovative medicines. Proceed to Site If you’re having trouble finding something specific please send an inquiry to investors@alnylam.com: Mar 24, 2020

Try using different or fewer filters.

Our Pipeline Clinical Trials Medical ... Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as clinical collaborators, will review recent progress in many of our pipeline programs and platform. Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.

Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock price as well as historical stock price data.

Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Links to all outside sites are provided as a reference for our visitors. Receive news and updates on the work at Alnylam that affects you most.To those who say “impossible, impractical, unrealistic,” we say:We are focused on diseases for which treatment options are limited or simply don't exist.Patients are at the core of everything we do. On July 17, 2020, we hosted an online RNAi Roundtable to review progress in our early stage RNAi therapeutics pipeline.Receive news and updates on the work at Alnylam that affects you most.New results and analyses of study data for ONPATTRO® (patisiran) were presented at the 2020 Peripheral Nerve Society (PNS) Annual Meeting, held June 27-30 as a virtual event.Positive results from the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic in development for the treatment of Primary Hyperoxaluria Type 1 (PH1), were presented by study investigators at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress, held June 6-9, 2020 as a virtual event.Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi into innovative medicines. For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we work to develop innovative medicines for patients. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Our robust pipeline contains therapies in late-stage (Phase 3) and early-stage (Phase 2 or earlier) trials.
Our second medicine, GIVLAARI® (givosiran), was approved by the FDA in 2019.
The data will be presented during the ILC 2020 (London, UK) which was rescheduled to August 25-28, 2020 due to the COVID-19 pandemic.On June 23, 2020, we hosted an online RNAi Roundtable to review the progress with ALN-AGT, an RNAi therapeutic in development for the treatment of hypertension.The following content may not be associated with Alnylam Pharmaceuticals. Date Description View/Download; There are currently no reports available that match your selection. Our Products Our Pipeline. Posted at 10:49h in Capella, Roundtables We are hosting a series of online "RNAi Roundtables" from June through September, at which Alnylam scientists, clinical collaborators, and patients or patient advocates review recent progress in many of the Company's late-stage …

Capella (Our Presentations) Our Products. You are now leaving Alnylam.com.
";s:7:"keyword";s:23:"Www alnylam com capella";s:5:"links";s:7267:"2019年ヒット曲邦楽, アマチュア無線 J クラスター, たけのこベーコンパスタ, 2006 ドイツ代表フォーメーション, 箕輪厚介アイメイク, 若年性アルツハイマー 20代ブログ, モンハン山田孝之作り方, アスタリア攻略 6周年, 柴崎岳の奥さんリフティング, 新幹線モーター全車両, ラストダンス歌詞ボカロ, 定期券男女ばれる, プレミアム商品券取り扱い店舗, 阪神競馬場駐車場 G1, 済美大阪桐蔭なんj, Something Somethings 違い, レモンサワーの素開封後賞味期限, 東京札幌飛行機時間, 山下智久好きな食べ物, モリアーティ Fgo 漫画, 京都バス均一区間路線図, するまでできない英語, 郵便番号鹿児島市桜ヶ丘, バイトクレーム辞めたい, ハイドンモーツァルトベートーヴェンシンフォニー, スピード類語英語, グレンダイザーマリアかわいい, 知らなくていいこと佐々木蔵之介かっこいい, 桧山最終打席なんj, 中山競馬場最高人数, プロスピ川端評価, アルツハイマーリコード法, 希望的 Refrain, 松田翔太身長サバ, フェデックス関税請求書いつ, マントウレシピふわふわ, 十文字高校経験点, ";s:7:"expired";i:-1;}